These foxes were included in the current study. Methods of transporting and storing the carcasses, examining the intestinal tracts, and identifying parasites have been described previously (2) .
Of 150 foxes examined, 19 animals from four counties (GyorSopron, Komárom-Esztergom, Pest, and Nógrád) harbored 2, 3, 4, 6, 7, 14, 22, 31, 51, 54, 114, 130, 200, 250, 300, 400, 800, and 1,300, and 5,500 mature worms of Echinococcus. On the basis of the most important morphometric guidelines and the results of the species-specific polymerase chain reaction (PCR) assay, the parasites were identified as E. multilocularis. The examined foxes were found from 5 to 70 km from the known endemic areas of the Slovak Republic, Austria, and Hungary, and from 5 to 50 km from the northern border of the country. On the basis of this information and the previous study (2) , the overall prevalence rate of infection was 16% (24/156) in the five northern counties of Hungary (Gyor-Sopron 30%, Nógrád 26%, Komárom-Esztergom 7%, Pest 6%, and BorsodAbaúj-Zemplén 5%). This prevalence rate is similar to those observed in Poland, Belgium, and the Slovak Republic in recent years. In these countries, a total of 30 human cases have been reported since 1995 (3) (4) (5) (6) .
In Germany, infected foxes were more frequently found near water (7), which indicates a water-related natural cycle of the parasite. The spatial aggregation analysis of the parasite in intermediate hosts demonstrated that areas with humid conditions are at high risk for human exposure (8) . In Europe, the most important waterrelated intermediate host of E. multilocularis is the water vole (Arvicola terrestris) (9) . The prevalence of E. multilocularis in water voles can be as high as 39% in disease-endemic areas (10). Areas with high water-vole densities yielded a 10-fold higher risk for alveolar echinococcosis in humans compared to areas with low densities (10). These data indicate that water voles may play an important role in the epidemiology of E. multilocularis. All infected foxes included in this and the previous study (2) were found near permanent natural waters, i.e., in those areas where water vole populations exist, such as Lake Ferto, the River Danube, the River Ipoly, the River Rába, and several streams connected to the watershed area of the River Danube. E. multilocularis might have spread in the northern part of Hungary along the watershed area of the River Danube, coming from the known disease-endemic areas of Austria and the Slovak Republic. Similar spreading of the parasite along waterways was also observed in the Slovak Republic (11).
In the historically known E. multilocularis-endemic mountain areas, both fossorial and aquatic water voles exist (12). The density of these populations can be 10-fold greater than that of aquatic populations in other European countries (12). On the basis of the long incubation period of the parasite in humans (5-15 years) and the dates of the first human cases reported outside the historically known area (Figure) , foxes might have reached the population density needed (13) to maintain the parasite cycle in low water-vole density areas in Europe from the 1980s (Figure) . Although the parasite crossed the border of several countries that surrounded the known area, further spreading was not observed in those countries where A. terrestris is an endangered species (the Netherlands, northern Italy) or where water voles are absent from the fauna (western and southern France) (12).
The River Danube and several small streams crossing Budapest, the capital of Hungary with a population of 2 million, create ideal circumstances for urbanization of the life cycle of a parasite that involves water voles and red foxes. Urbanization of the life cycle of E. multilocularis was recently observed in Prague, the capital of the Czech Republic with a population of 1 million and similar hydrographic features (14); therefore, occurrences of this zoonosis should be continuously monitored in Budapest. Further studies are necessary to monitor the possible spread of the parasite in other regions that are thought to be currently free of the infection.
The regulatory, veterinary, and public health authorities of the European Union mobilized considerable financial and human resources to control rabies and paid less attention to alveolar echinococcosis in the 1990s, although incidence data indicate that alveolar echinococcosis is increasing and became an emerging infectious disease in Europe. In the Directive 2003/99/EC of the European Parliament and of the Council repealing Council Directive 92/117/EEC, echinococcosis has been added to the list of zoonoses to be monitored in the European Union countries. Effective methods to control E. multilocularis are unavailable; however, the zoonosis should be monitored and evaluated, and development of control programs should be intensified. (1) . The fluoroquinolone enrofloxacin was approved in 1996 for therapeutic use by addition to drinking water upon the decision of a licensed veterinarian "for the control of mortality in chickens associated with Escherichia coli organisms and control of mortality in turkeys associated with E. coli and Pasteurella multocida organisms" (2) . This therapeutic use was withdrawn (3) but is now under appeal. Initial approval and subsequent efforts to withdraw use of enrofloxacin in the United States parallel the earlier trend in Europe and specifically Denmark, where the use of antimicrobial agents as growth promoters has been banned (4).
Enrofloxacin is not approved for prophylactic or growth promotion use in poultry feed as stated in our commentary and in the first section of the flowchart (1). However, when enrofloxacin is added to the drinking water of poultry, large numbers of both ill and healthy animals are exposed to the agent (5) . Although extra-label use of enrofloxacin is prohibited, microbiologic culture of either of the cited bacteria is not required before administration (2) . Despite the restrictions on enrofloxacin use, emergence of fluoroquinolone-resistant Campylobacter species, with poultry as an important source, has been documented in the United States (5, 6) . Thus the decision to withdraw therapeutic use of enrofloxacin (3) 
